<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang xml:lang>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Your Digest for Wednesday, Aug 30, 2023 09:59 PM</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    span.underline{text-decoration: underline;}
    div.column{display: inline-block; vertical-align: top; width: 50%;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
  </style>
  <style type="text/css">
:root,
::backdrop {

--sans-font: -apple-system, BlinkMacSystemFont, "Avenir Next", Avenir,
"Nimbus Sans L", Roboto, "Noto Sans", "Segoe UI", Arial, Helvetica,
"Helvetica Neue", sans-serif;
--mono-font: Consolas, Menlo, Monaco, "Andale Mono", "Ubuntu Mono", monospace;
--standard-border-radius: 5px;

--bg: #fff;
--accent-bg: #f5f7ff;
--text: #212121;
--text-light: #585858;
--border: #898EA4;
--accent: #0d47a1;
--code: #d81b60;
--preformatted: #444;
--marked: #ffdd33;
--disabled: #efefef;
}

@media (prefers-color-scheme: dark) {
:root,
::backdrop {
color-scheme: dark;
--bg: #212121;
--accent-bg: #2b2b2b;
--text: #dcdcdc;
--text-light: #ababab;
--accent: #ffb300;
--code: #f06292;
--preformatted: #ccc;
--disabled: #111;
}

img,
video {
opacity: 0.8;
}
}

*, *::before, *::after {
box-sizing: border-box;
}

textarea,
select,
input,
progress {
appearance: none;
-webkit-appearance: none;
-moz-appearance: none;
}
html {

font-family: var(--sans-font);
scroll-behavior: smooth;
}

body {
color: var(--text);
background-color: var(--bg);
font-size: 1.15rem;
line-height: 1.5;
display: grid;
grid-template-columns: 1fr min(45rem, 90%) 1fr;
margin: 0;
}
body > * {
grid-column: 2;
}

body > header {
background-color: var(--accent-bg);
border-bottom: 1px solid var(--border);
text-align: center;
padding: 0 0.5rem 2rem 0.5rem;
grid-column: 1 / -1;
}
body > header h1 {
max-width: 1200px;
margin: 1rem auto;
}
body > header p {
max-width: 40rem;
margin: 1rem auto;
}

main {
padding-top: 1.5rem;
}
body > footer {
margin-top: 4rem;
padding: 2rem 1rem 1.5rem 1rem;
color: var(--text-light);
font-size: 0.9rem;
text-align: center;
border-top: 1px solid var(--border);
}

h1 {
font-size: 3rem;
}
h2 {
font-size: 2.6rem;
margin-top: 3rem;
}
h3 {
font-size: 2rem;
margin-top: 3rem;
}
h4 {
font-size: 1.44rem;
}
h5 {
font-size: 1.15rem;
}
h6 {
font-size: 0.96rem;
}

p, h1, h2, h3, h4, h5, h6 {
overflow-wrap: break-word;
}

h1,
h2,
h3 {
line-height: 1.1;
}

@media only screen and (max-width: 720px) {
h1 {
font-size: 2.5rem;
}
h2 {
font-size: 2.1rem;
}
h3 {
font-size: 1.75rem;
}
h4 {
font-size: 1.25rem;
}
}

a,
a:visited {
color: var(--accent);
}
a:hover {
text-decoration: none;
}
button,
.button,
a.button, 
input[type="submit"],
input[type="reset"],
input[type="button"],
label[type="button"] {
border: none;
border-radius: var(--standard-border-radius);
background-color: var(--accent);
font-size: 1rem;
color: var(--bg);
padding: 0.7rem 0.9rem;
margin: 0.5rem 0;
text-decoration: none;
font-family: inherit;
line-height: normal;
}
.button[aria-disabled="true"], input:disabled,
textarea:disabled,
select:disabled,
button[disabled] {
cursor: not-allowed;
background-color: var(--disabled);
color: var(--text-light)
}
input[type="range"] {
padding: 0;
}

abbr[title] {
cursor: help;
text-decoration-line: underline;
text-decoration-style: dotted;
}
button:enabled:hover,
.button:not([aria-disabled="true"]):hover,
input[type="submit"]:enabled:hover,
input[type="reset"]:enabled:hover,
input[type="button"]:enabled:hover,
label[type="button"]:hover {
filter: brightness(1.4);
cursor: pointer;
}
.button:focus-visible,
button:focus-visible:where(:enabled),
input:enabled:focus-visible:where(
[type="submit"],
[type="reset"],
[type="button"]
) {
outline: 2px solid var(--accent);
outline-offset: 1px;
}

header > nav {
font-size: 1rem;
line-height: 2;
padding: 1rem 0 0 0;
}

header > nav ul,
header > nav ol {
align-content: space-around;
align-items: center;
display: flex;
flex-direction: row;
flex-wrap: wrap;
justify-content: center;
list-style-type: none;
margin: 0;
padding: 0;
}

header > nav ul li,
header > nav ol li {
display: inline-block;
}
header > nav a,
header > nav a:visited {
margin: 0 0.5rem 1rem 0.5rem;
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
color: var(--text);
display: inline-block;
padding: 0.1rem 1rem;
text-decoration: none;
}
header > nav a:hover,
header > nav a.current,
header > nav a[aria-current="page"] {
border-color: var(--accent);
color: var(--accent);
cursor: pointer;
}

@media only screen and (max-width: 720px) {
header > nav a {
border: none;
padding: 0;
text-decoration: underline;
line-height: 1;
}
}

aside, details, pre, progress {
background-color: var(--accent-bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
aside {
font-size: 1rem;
width: 30%;
padding: 0 15px;
margin-inline-start: 15px;
float: right;
}
*[dir="rtl"] aside {
float: left;
}

@media only screen and (max-width: 720px) {
aside {
width: 100%;
float: none;
margin-inline-start: 0;
}
}
article, fieldset, dialog {
border: 1px solid var(--border);
padding: 1rem;
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
article h2:first-child,
section h2:first-child {
margin-top: 1rem;
}
section {
border-top: 1px solid var(--border);
border-bottom: 1px solid var(--border);
padding: 2rem 1rem;
margin: 3rem 0;
}

section + section,
section:first-child {
border-top: 0;
padding-top: 0;
}
section:last-child {
border-bottom: 0;
padding-bottom: 0;
}
details {
padding: 0.7rem 1rem;
}
summary {
cursor: pointer;
font-weight: bold;
padding: 0.7rem 1rem;
margin: -0.7rem -1rem;
word-break: break-all;
}
details[open] > summary + * {
margin-top: 0;
}
details[open] > summary {
margin-bottom: 0.5rem;
}
details[open] > :last-child {
margin-bottom: 0;
}

table {
border-collapse: collapse;
margin: 1.5rem 0;
}
td,
th {
border: 1px solid var(--border);
text-align: start;
padding: 0.5rem;
}
th {
background-color: var(--accent-bg);
font-weight: bold;
}
tr:nth-child(even) {

background-color: var(--accent-bg);
}
table caption {
font-weight: bold;
margin-bottom: 0.5rem;
}

textarea,
select,
input {
font-size: inherit;
font-family: inherit;
padding: 0.5rem;
margin-bottom: 0.5rem;
color: var(--text);
background-color: var(--bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
box-shadow: none;
max-width: 100%;
display: inline-block;
}
label {
display: block;
}
textarea:not([cols]) {
width: 100%;
}

select:not([multiple]) {
background-image: linear-gradient(45deg, transparent 49%, var(--text) 51%),
linear-gradient(135deg, var(--text) 51%, transparent 49%);
background-position: calc(100% - 15px), calc(100% - 10px);
background-size: 5px 5px, 5px 5px;
background-repeat: no-repeat;
padding-inline-end: 25px;
}
*[dir="rtl"] select:not([multiple]) {
background-position: 10px, 15px;
}

input[type="checkbox"],
input[type="radio"] {
vertical-align: middle;
position: relative;
width: min-content;
}
input[type="checkbox"] + label,
input[type="radio"] + label {
display: inline-block;
}
input[type="radio"] {
border-radius: 100%;
}
input[type="checkbox"]:checked,
input[type="radio"]:checked {
background-color: var(--accent);
}
input[type="checkbox"]:checked::after {

content: " ";
width: 0.18em;
height: 0.32em;
border-radius: 0;
position: absolute;
top: 0.05em;
left: 0.17em;
background-color: transparent;
border-right: solid var(--bg) 0.08em;
border-bottom: solid var(--bg) 0.08em;
font-size: 1.8em;
transform: rotate(45deg);
}
input[type="radio"]:checked::after {

content: " ";
width: 0.25em;
height: 0.25em;
border-radius: 100%;
position: absolute;
top: 0.125em;
background-color: var(--bg);
left: 0.125em;
font-size: 32px;
}

@media only screen and (max-width: 720px) {
textarea,
select,
input {
width: 100%;
}
}

input[type="color"] {
height: 2.5rem;
padding: 0.2rem;
}

input[type="file"] {
border: 0;
}

hr {
border: none;
height: 1px;
background: var(--border);
margin: 1rem auto;
}
mark {
padding: 2px 5px;
border-radius: var(--standard-border-radius);
background-color: var(--marked);
color: black;
}
img,
video {
max-width: 100%;
height: auto;
border-radius: var(--standard-border-radius);
}
figure {
margin: 0;
display: block;
overflow-x: auto;
}
figcaption {
text-align: center;
font-size: 0.9rem;
color: var(--text-light);
margin-bottom: 1rem;
}
blockquote {
margin-inline-start: 2rem;
margin-inline-end: 0;
margin-block: 2rem;
padding: 0.4rem 0.8rem;
border-inline-start: 0.35rem solid var(--accent);
color: var(--text-light);
font-style: italic;
}
cite {
font-size: 0.9rem;
color: var(--text-light);
font-style: normal;
}
dt {
color: var(--text-light);
}

code,
pre,
pre span,
kbd,
samp {
font-family: var(--mono-font);
color: var(--code);
}
kbd {
color: var(--preformatted);
border: 1px solid var(--preformatted);
border-bottom: 3px solid var(--preformatted);
border-radius: var(--standard-border-radius);
padding: 0.1rem 0.4rem;
}
pre {
padding: 1rem 1.4rem;
max-width: 100%;
overflow: auto;
color: var(--preformatted);
}

pre code {
color: var(--preformatted);
background: none;
margin: 0;
padding: 0;
}



progress {
width: 100%;
}
progress:indeterminate {
background-color: var(--accent-bg);
}
progress::-webkit-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent-bg);
}
progress::-webkit-progress-value {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
}
progress::-moz-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
transition-property: width;
transition-duration: 0.3s;
}
progress:indeterminate::-moz-progress-bar {
background-color: var(--accent-bg);
}
dialog {
max-width: 40rem;
margin: auto;
}
dialog::backdrop {
background-color: var(--bg);
opacity: 0.8;
}
@media only screen and (max-width: 720px) {
dialog {
max-width: 100%;
margin: auto 1em;
}
}

.notice {
background: var(--accent-bg);
border: 2px solid var(--border);
border-radius: 5px;
padding: 1.5rem;
margin: 2rem 0;
}

strong{
color:#d81b60;
}
em {
color:#e0467e; 
}
hr
{
border: 1px;
clear: both;
display: block;
width: 100%;
height: 1px;

background-color:#686868
}
</style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">Your Digest for Wednesday, Aug 30, 2023 09:59 PM</h1>
</header>
<hr />
<p>In parathyroid cells, the extracellular calcium-sensing receptor regulates the secretion of PTH</p>
<p>PTH inhibits the proximal tubular transport of phosphate from the lumen to the interstitium. In conditions of primary PTH excess, hypophosphatemia tends to occur. Conversely, in hypoparathyroidism, the phosphate concentration in the plasma is within the reference range or slightly elevated.</p>
<p>PTH stimulates renal 1-alpha-hydroxylase, the enzyme that synthesizes formation of 1,25-dihydroxy vitamin D; 1,25-dihydroxy vitamin D allows for better dietary calcium absorption. Thus, 1,25-dihydroxy vitamin D has a synergistic effect with PTH; both contribute to a rise in the ECF ionized calcium concentration.</p>
<p>In the absence of PTH, bone resorption, phosphaturic effect, renal distal tubular calcium reabsorption, and 1,25-dihydroxy vitamin Dâ€“mediated dietary calcium absorption cannot occur. Therefore, the consequence of PTH deficiency is hypocalcemia.</p>
<h2 id="pseudohypoparathyroidism-php">Pseudohypoparathyroidism (PHP)</h2>
<p>Not absense of PTH, but <em>resistance</em> to PTH.<br />
Causes hypocalcemia, hyperphosphatemia, and elevated PTH levels.<br />
It is actually a group of disorders.</p>
<p>These patients have &#39;PTH resistant hypocalcemia&#39;.<br />
The classical presentation was<br />
short stature, rounded face, shortened fourth metacarpals and other bones of the hands and feet, obesity, dental hypoplasia, and soft-tissue calcifications/ossifications.</p>
<ul>
<li>i.e Albright Hereditary Osteodystrophy. (this is seen in most but not all types of PHP)</li>
</ul>
<p>Diagnosis of PHP is defined by the coexistence of hypocalcemia and hyperphosphatemia with elevated PTH levels in the presence of normal vitamin D values and normal renal function and the ? absence of hypercalciuria</p>
<blockquote>
<p>In pseudohypoparathyroidism, monitoring serum PTH levels during treatment is critical with the aim of normalizing or reducing PTH levels as much as possible. This is done to avoid the long-term elevation of circulating PTH, that would likely cause bone resorption. Also, hypercalciuria as a result of the calcitriol and calcium treatment is a lesser concern because PTH actions in the distal tubule are functional, preventing the loss of calcium in the urine.</p>
</blockquote>
<p><a href="https://www.ncbi.nlm.nih.gov/books/NBK279165/">https://www.ncbi.nlm.nih.gov/books/NBK279165/</a></p>
<p>Fuller Albright reported patients with pseudohypoparathyroidism who had short stature, obesity, round facies, shortened metacarpals and metatarsals, and PTH resistance causing hypocalcaemia and hyperphosphataemia in 1942.<br />
In 1952 he described patients with the same physical appearance but without PTH resistance, a condition that he termed pseudopseudohypoparathyroidism</p>
<p>Maternal transmission causes pseudohypoparathyroidism type 1a whereas paternal transmission leads to pseudopseudohypoparathyroidism, a phenomenon known as genomic imprinting.<br />
Renal tubular cells predominantly express the maternal allele of GNAS so a paternally inherited mutation results in a normal renal response to PTH</p>
<p>. PHPP is caused by genetic changes in the GNAS gene and is inherited in an autosomal dominant fashion.</p>
<p>This condition is usually inherited from the father (genomic imprinting). PPHP is genetically related to pseudohypoparathyroidism type Ia (PHP-1a). Signs and symptoms are similar, however people with PPHP do not show resistance to parathyroid hormone while people with PHP-1a do</p>
<p>This condition is usually inherited from the father (genomic imprinting). PPHP is genetically related to pseudohypoparathyroidism type Ia (PHP-1a). Signs and symptoms are similar, however people with PPHP do not show resistance to parathyroid hormone while people with PHP-1a do</p>
<hr />
<h2 id="sglt-2-inhibitors">SGLT-2 inhibitors</h2>
<p>Canagliflozin, dapagliflozin, empagliflozin</p>
<p>Mechanism: Inhibit the SGLT-2 transporter in the <strong>proximal convoluted tubule</strong> and reduce the &#39;<em>renal threshold for glucose</em>&#39;.</p>
<hr />
<p>Can cause gum bleeding -&gt; bleeding from such sites can be caused by a problem with the blood vessels and not a coagulopathy.</p>
<h1 id="lymphoma">Lymphoma</h1>
<p>NHL is an AIDS defining illness.<br />
Can preset with pancytopenia and <em>rapidly enlarging</em> lymphadenopathy.<br />
LDH is elevated</p>
<hr />
<blockquote>

</blockquote>
<h2 id="pathogenesis">Pathogenesis</h2>
<p>Plasma cells undergo mutations that <em>restore their capacity for proliferation</em>.<br />
Monoclonal plasma cells proliferate in bone marrow.<br />
MGUS (&lt;10% myeloma cells in marrow )-&gt; Smouldering myeloma (&gt;10% myeloma cells in marrow )-&gt; multiple myeloma</p>
<p>Renal involvement is <strong>one of the commonest</strong> complications of multiple myeloma.(50% incidence!)</p>
<ol>
<li>Light chains -&gt; freely filtered at glomerulus -&gt; resorbed but resorbtive capacity exceeded in MM -&gt; precipitate in the tubule in combination with Tamm-horsfalal proteins-&gt; <em>cast nephropathy</em>. <em>Usually presents as Acute or subacute kidney injury</em>.
<ol>
<li>Light chains appear in urine as Bence Jones proteins.<br />
Another mechanism of renal injury:<br />
<strong>AL amyloidosis</strong>, caused by myeloma light chains, results in glomerular deposition of AL amyloid in the mesangial, subepithelial, or subendothelial areas or a combination.<br />
Amyloid deposition is with randomly oriented, nonbranching <strong>fibrils</strong> composed of the variable regions of lambda light chains.</li>
</ol></li>
</ol>
<blockquote>
<p>&quot;Light chain deposition disease&quot;, which also can occur with lymphoma and macroglobulinemia, is glomerular deposition of nonpolymerized light chains (ie, <em>without fibrils</em>), generally the constant regions of kappa chains.</p>
</blockquote>
<hr />
<ul>
<li>The two commonest organisms are Strep pneumoniae and N. meningitidis.</li>
<li>The incidence of Listeria monocytogenes meningitis increases with age.</li>
</ul>
<table>
<thead>
<tr class="header">
<th>Age</th>
<th>Causative organisms</th>
<th>Empiric ABx</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>2 - 50 years</td>
<td>Neisseria meningitidis</td>
<td>Vancomycin + Gen 3 cephalosporin</td>
<td></td>
</tr>
<tr class="even">
<td>&gt; 50 years</td>
<td><strong>Strep. pneumoniae</strong>, <strong>N. meningitidis</strong>, Listeria monocytogenes, aerobic gram -ve bacilli.</td>
<td>Vancomycin + ampicillin + Gen 3 cephalosporin</td>
<td></td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr class="header">
<th>trauma</th>
<th>organism</th>
<th>empiric ABx</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Basilar skull fracture</td>
<td><em>S. pneumoniae</em>, <em>H. influenzae</em>, group A beta-hemolytic streptococci</td>
<td>Vancomycin plus a third-generation cephalosporin</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>Penetrating trauma</td>
<td><em>Staphylococcus aureus</em>, coagulase-negative staphylococci (especially <em>Staphylococcus epidermidis</em>), aerobic gram-negative bacilli (including <em>Pseudomonas aeruginosa</em>)</td>
<td>Vancomycin plus cefepime; OR vancomycin plus ceftazidime; OR vancomycin plus meropenem</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="antibiotics-in-meningitis">Antibiotics in meningitis</h3>
<h4 id="common-considerations-of-antitibiotics-used-in-meningitis">Common considerations of antitibiotics used in meningitis.</h4>
<ul>
<li>Bactericidal antibiotics are superior to bacteriostatic antibiotics.</li>
<li>Most beta lactam agents penetrate the BBB poorly, except during inflammation. As inflammation resolves, antibiotic penetration decreases. High doses should be continued throughout the course of treatment.</li>
<li><strong>Beta lactams and vancomycin</strong> display <strong>time dependent</strong> activity.
<ul>
<li>(i.e bactericidal activity depends on the <strong>time</strong> that the agent is above the <em>minimum inhibitory concentration as a proportion of the dosing interval</em>.</li>
</ul></li>
<li><strong>Aminoglycosides</strong> display <strong>concentration dependent</strong> antimicrobial activity. They show a <strong>post antibiotic effect</strong>.</li>
</ul>
<h4 id="specifics">Specifics</h4>
<ul>
<li>Selected Gen 3 cephalosporins are the beta lactams of choice in meningitis. (<strong>cefotaxime and ceftriaxone</strong>)</li>
<li>Gen 3 cephalosporins are <strong>inactive</strong> against Listeria and some penicillin resistant strains of Strep. pneumoniae.</li>
<li>Listeria is sensitive to <strong>ampicillin</strong>.</li>
<li>Vancomycin is added as empiric treatment against penicillin resistant strep. pneumoniae.</li>
</ul>
<h4 id="listeria-monocytogenes">Listeria monocytogenes</h4>
<p>Listeria is a beta haemolytic gram +ve bacillus.<br />
They are ubiquitous in the environment and can be present in the human gut.<br />
They can easily contaminate food and infection is via ingestion. They can even survive and <strong>reproduce</strong> at refrigerator temperatures.<br />
Ingestion can cause <strong>febrile gastroenteritis</strong>.<br />
They multiply <em>intracellularly</em> and therefore, require cell mediated immunity for control.<br />
Therefore, following groups are at risk;</p>
<ul>
<li>Elderly</li>
<li>Neonates</li>
<li>Pregnant women - Mother usually has mild illness; Choriamnionitis -&gt; transplancental spread -&gt; spotaneous abortion, early infant death are the risks.</li>
<li>Immunocompromised patients</li>
</ul>
<p>In at risk patients, bacteraemia leads to high fever without localizing signs leading to endocarditis, peritonitis, osteomyelitis, septic arthritis, cholecystitis and pneumonia, <strong>meningitis</strong> and occuloglandular listeriosis (ophthalmitis and lymph node enlargement - Parinaud syndrome).</p>
<p><strong>Treatment</strong>: Ceftriaxones are ineffective. Ampicillin + gentamicin (as this combination shows synergy)</p>
<hr />
<h2 id="cephalosporins">Cephalosporins</h2>
<blockquote>
<p>[!INFO] Development of cephalosporins<br />
In 1945, after penicillin had been introduced into medicine, an antibiotic-producing species of Cephalosporium was isolated from a sewage outfall in Sardinia. Four years later in Oxford, this organism was found to produce several antibiotics, one of which was a penicillin with a new side-chain, penicillin N. During a chemical study in 1953, this penicillin was shown to be contaminated with a second substance, cephalosporin C, which contained a beta-lactam ring but was resistant to hydrolysis by a penicillinase (beta-lactamase). At that time, penicillinase-producing Staphylococci were causing a serious problem in hospitals. The isolation of the nucleus of cephalosporin C (7-ACA) enabled pharmaceutical manufacturers to produce many thousands of cephalosporins, some of which have been effective in the treatment of serious infections by a number of Gram-positive and Gram-negative bacteria.</p>
</blockquote>
<p>Mechanism of action: They are beta lactam antibiotics; Mechanism of action: inhibition of bacterial cell wall synthesis</p>
<p><a href="https://www.medigraphic.com/pdfs/lamicro/mi-2007/mi07-3_4g.pdf">https://www.medigraphic.com/pdfs/lamicro/mi-2007/mi07-3_4g.pdf</a></p>
<h3 id="gen-1-cefazolin-cephalexin">gen 1: Cefazolin, Cephalexin</h3>
<p>First generation : most gram +ve cocci and some gram negative bacteria<br />
(including <em>penicillinase-producing Staphylococcus aureus</em>)<br />
&quot;minimal coverage of gram -ves&quot; but a few Gram -ves are susceptible.<br />
(gram -ve&#39;s including E coli, klebsiella, proteus).<br />
Clinically used for uncomplicated skin and soft tissue infections.</p>
<h3 id="gen-2">Gen 2:</h3>
<p>Cefuroxime<br />
Haemophilus infeluenza, Moraxella, bacteroides</p>
<p>cefuroxime has increased coverage against H. influenzae.</p>
<p>Second-generation cephalosporins have less activity against gram-positive cocci than first-generation cephalosporins but <em>have increased activity against gram-negative bacilli</em></p>
<p>They are often prescribed to treat respiratory infections such as bronchiolitis or pneumonia.</p>
<p>In addition to the gram-negative bacteria covered by first-generation cephalosporins, second-generation cephalosporins also have coverage against H. influenzae, Enterobacter aerogenes, Neisseria species, and Serratia marcescens</p>
<h3 id="gen-3">Gen 3:</h3>
<p><strong>Less coverage against gram +ves</strong> but increased coverage Enterobacteriaceai, Neisseria and H influenzae.</p>
<h3 id="gen-4">Gen 4:</h3>
<p>similar to gen 3 but better activity against gram -ves with <em>antimicrobial resistance</em>. (like beta lactamases)</p>
<h3 id="gen-5">Gen 5:</h3>
<p>have coverage against MRSA and penicillin resistant pneumococci.</p>
<h1 id="haemophillus">Haemophillus</h1>
<p><a href="https://www.msdmanuals.com/professional/infectious-diseases/gram-negative-bacilli/haemophilus-infections">https://www.msdmanuals.com/professional/infectious-diseases/gram-negative-bacilli/haemophilus-infections</a><br />
Fastidious gram -ve cocco-bacillus.</p>
<p>bacteremia, meningitis, pneumonia, sinusitis, otitis media, cellulitis, and epiglottitis</p>
<p>the most common is H. influenzae, which has 6 distinct encapsulated serotypes (a through f) and numerous nonencapsulated, nontypeable strains. Before the use of H. influenzae type b (Hib) conjugate vaccine, most cases of serious, invasive disease were caused by type b.</p>
<p>Non typable strains can cause upto half of H influenze infections in adults.</p>
</body>
</html>
